Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
Atm | |
NM_007499 |
ataxia telangiectasia mutated homolog (human) (Atm), mRNA [NM_007499] |
KLA | 1.86 |
1.97 |
2.17 |
1.67 |
1.20 |
.86 |
.79 |
| ATP | 1.09 |
1.17 |
1.01 |
.97 |
.61 |
.63 |
.69 |
| KLA/ATP | 2.11 |
2.24 |
1.55 |
1.46 |
.85 |
.75 |
.59 |
|
Bcl10 | |
AK080820 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230313B18 product:unclassifiable, full insert sequence [AK080820] |
KLA | 1.44 |
1.52 |
1.23 |
1.38 |
1.54 |
1.25 |
1.08 |
| ATP | 1.31 |
1.35 |
1.59 |
1.40 |
3.05 |
2.29 |
.90 |
| KLA/ATP | 1.58 |
2.14 |
1.93 |
1.47 |
2.94 |
1.95 |
1.33 |
|
Bcl10 | |
NM_009740 |
B-cell leukemia/lymphoma 10 (Bcl10), mRNA [NM_009740] |
KLA | 1.63 |
1.57 |
1.42 |
1.42 |
1.52 |
1.04 |
1.14 |
| ATP | 1.10 |
1.12 |
1.04 |
1.06 |
1.97 |
2.63 |
1.15 |
| KLA/ATP | 1.40 |
1.58 |
1.36 |
1.27 |
1.54 |
1.87 |
1.51 |
|
Bcl2 | |
NM_009741 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] |
KLA | .30 |
.26 |
.25 |
.25 |
.34 |
.38 |
.26 |
| ATP | .97 |
.89 |
1.50 |
1.04 |
.99 |
.29 |
.52 |
| KLA/ATP | .28 |
.26 |
.40 |
.33 |
.62 |
.29 |
.12 |
|
Bcl2 | |
NM_177410 |
B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] |
KLA | .33 |
.33 |
.37 |
.42 |
.49 |
.46 |
.39 |
| ATP | 1.07 |
1.12 |
1.22 |
1.56 |
1.00 |
.38 |
.76 |
| KLA/ATP | .35 |
.34 |
.54 |
.89 |
.76 |
.36 |
.23 |
|
Bcl2a1b | |
NM_007534 |
B-cell leukemia/lymphoma 2 related protein A1b (Bcl2a1b), mRNA [NM_007534] |
KLA | 34.11 |
34.56 |
37.57 |
36.91 |
28.13 |
17.63 |
10.35 |
| ATP | 1.02 |
1.06 |
1.87 |
3.05 |
8.81 |
14.40 |
6.63 |
| KLA/ATP | 34.55 |
35.44 |
49.51 |
38.70 |
36.65 |
17.92 |
12.39 |
|
Bcl2a1c | |
NM_007535 |
B-cell leukemia/lymphoma 2 related protein A1c (Bcl2a1c), mRNA [NM_007535] |
KLA | 33.96 |
35.89 |
36.34 |
38.52 |
29.20 |
19.48 |
11.43 |
| ATP | 1.01 |
1.08 |
1.84 |
2.98 |
8.29 |
13.22 |
6.74 |
| KLA/ATP | 30.56 |
34.60 |
50.13 |
43.72 |
35.49 |
19.36 |
15.41 |
|
Bcl2l1 | |
NM_009743 |
Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] |
KLA | .99 |
1.02 |
1.10 |
1.16 |
1.27 |
.97 |
1.05 |
| ATP | 1.18 |
1.42 |
.81 |
1.26 |
1.51 |
.71 |
1.67 |
| KLA/ATP | 1.21 |
1.30 |
.66 |
1.15 |
1.31 |
1.17 |
1.59 |
|
Birc2 | |
NM_007465 |
baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] |
KLA | 4.63 |
4.59 |
3.77 |
2.79 |
2.32 |
2.07 |
1.84 |
| ATP | .95 |
.88 |
.84 |
.92 |
.76 |
1.34 |
1.28 |
| KLA/ATP | 4.70 |
4.93 |
4.13 |
2.60 |
1.34 |
1.60 |
2.31 |
|
Birc3 | |
BC011338 |
baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] |
KLA | 5.48 |
5.46 |
4.94 |
4.16 |
4.91 |
3.36 |
3.74 |
| ATP | 1.05 |
1.08 |
4.21 |
4.28 |
2.59 |
2.55 |
1.57 |
| KLA/ATP | 6.78 |
8.91 |
11.01 |
4.87 |
2.28 |
2.12 |
3.66 |
|
Birc3 | |
NM_007464 |
baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] |
KLA | 17.83 |
15.88 |
13.48 |
11.14 |
11.79 |
6.90 |
6.10 |
| ATP | 1.14 |
1.16 |
1.70 |
4.07 |
5.00 |
6.33 |
2.41 |
| KLA/ATP | 14.77 |
16.44 |
19.09 |
13.91 |
8.27 |
6.22 |
7.73 |
|
Blnk | |
NM_008528 |
B-cell linker (Blnk), mRNA [NM_008528] |
KLA | 1.53 |
1.39 |
1.23 |
1.31 |
1.01 |
1.41 |
1.21 |
| ATP | .95 |
.81 |
1.09 |
.87 |
2.09 |
1.28 |
.97 |
| KLA/ATP | 1.21 |
1.23 |
1.44 |
1.00 |
2.09 |
1.88 |
1.39 |
|
Btk | |
NM_013482 |
Bruton agammaglobulinemia tyrosine kinase (Btk), mRNA [NM_013482] |
KLA | 1.10 |
1.24 |
1.01 |
1.33 |
1.07 |
1.27 |
1.01 |
| ATP | .95 |
1.05 |
.86 |
.97 |
.66 |
.72 |
.82 |
| KLA/ATP | 1.14 |
1.35 |
1.12 |
1.52 |
.96 |
.70 |
.82 |
|
Card11 | |
AK002346 |
adult male kidney cDNA, RIKEN full-length enriched library, clone:0610008L17 product:CASPASE RECRUITMENT DOMAIN PROTEIN 11 (CARD-CONTAINING MAGUK PROTEIN 3) (CARMA 1) homolog [Homo sapiens], full insert sequence. [AK002346] |
KLA | .83 |
.86 |
.89 |
.91 |
1.13 |
.99 |
.99 |
| ATP | .97 |
.93 |
.89 |
.93 |
.88 |
.89 |
.98 |
| KLA/ATP | .91 |
.87 |
.89 |
.86 |
.88 |
.92 |
1.01 |
|
Card11 | |
NM_175362 |
caspase recruitment domain family, member 11 (Card11), mRNA [NM_175362] |
KLA | .33 |
.29 |
.31 |
.44 |
.71 |
1.30 |
1.45 |
| ATP | .84 |
.68 |
.79 |
.71 |
.38 |
.26 |
.47 |
| KLA/ATP | .33 |
.27 |
.40 |
.35 |
.38 |
.37 |
.85 |
|
Ccl19 | |
NM_011888 |
chemokine (C-C motif) ligand 19 (Ccl19), mRNA [NM_011888] |
KLA | 1.12 |
1.20 |
1.11 |
1.09 |
1.08 |
1.01 |
1.05 |
| ATP | .93 |
.99 |
1.01 |
1.01 |
.98 |
.95 |
1.03 |
| KLA/ATP | 1.12 |
1.21 |
1.16 |
1.13 |
1.08 |
.98 |
1.03 |
|
Ccl21b | |
NM_011124 |
chemokine (C-C motif) ligand 21b (Ccl21b), mRNA [NM_011124] |
KLA | 1.02 |
.97 |
.96 |
1.03 |
1.05 |
1.04 |
1.03 |
| ATP | .97 |
1.00 |
1.01 |
1.01 |
.94 |
1.03 |
1.01 |
| KLA/ATP | 1.08 |
.97 |
.96 |
1.00 |
1.06 |
1.03 |
1.02 |
|
Ccl4 | |
NM_013652 |
chemokine (C-C motif) ligand 4 (Ccl4), mRNA [NM_013652] |
KLA | 68.93 |
60.20 |
52.12 |
67.06 |
35.78 |
15.78 |
8.82 |
| ATP | 2.26 |
3.82 |
16.88 |
43.14 |
26.67 |
9.47 |
6.75 |
| KLA/ATP | 59.57 |
71.75 |
133.98 |
193.53 |
81.76 |
15.96 |
7.62 |
|
Cd14 | |
NM_009841 |
CD14 antigen (Cd14), mRNA [NM_009841] |
KLA | 2.35 |
2.68 |
2.54 |
2.21 |
2.39 |
1.52 |
1.57 |
| ATP | 1.44 |
2.28 |
2.82 |
3.98 |
6.68 |
16.14 |
6.92 |
| KLA/ATP | 2.92 |
3.79 |
3.96 |
5.12 |
5.29 |
10.42 |
11.50 |
|
Cd40 | |
NM_170701 |
CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] |
KLA | 23.87 |
23.62 |
23.26 |
23.98 |
22.07 |
17.37 |
5.34 |
| ATP | 1.00 |
1.01 |
1.06 |
2.96 |
2.65 |
3.03 |
1.70 |
| KLA/ATP | 22.77 |
23.79 |
29.67 |
28.85 |
28.08 |
21.62 |
13.02 |
|
Cd40lg | |
NM_011616 |
CD40 ligand (Cd40lg), mRNA [NM_011616] |
KLA | 1.03 |
1.07 |
1.02 |
.98 |
1.06 |
1.06 |
1.03 |
| ATP | .95 |
.92 |
.99 |
1.06 |
1.02 |
1.04 |
1.07 |
| KLA/ATP | 1.00 |
1.01 |
.93 |
1.04 |
.94 |
1.01 |
.98 |
|
Cflar | |
NM_009805 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 2, mRNA [NM_009805] |
KLA | 18.63 |
20.03 |
20.30 |
17.44 |
17.99 |
11.88 |
7.25 |
| ATP | .95 |
1.03 |
1.20 |
2.78 |
4.04 |
3.45 |
3.30 |
| KLA/ATP | 19.31 |
19.09 |
11.65 |
13.57 |
7.62 |
6.20 |
11.21 |
|
Cflar | |
NM_207653 |
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 1, mRNA [NM_207653] |
KLA | 12.32 |
12.86 |
11.83 |
11.79 |
12.14 |
8.52 |
5.42 |
| ATP | .92 |
.92 |
1.63 |
4.97 |
7.95 |
5.18 |
2.39 |
| KLA/ATP | 12.27 |
13.57 |
13.15 |
12.79 |
10.27 |
7.71 |
8.32 |
|
Cflar | |
Y14041 |
mRNA for CASH alpha protein. [Y14041] |
KLA | 14.31 |
13.82 |
13.05 |
13.06 |
14.36 |
9.02 |
5.92 |
| ATP | 1.18 |
1.15 |
1.66 |
6.44 |
8.99 |
5.20 |
2.73 |
| KLA/ATP | 15.53 |
17.07 |
14.00 |
17.10 |
10.76 |
8.02 |
9.97 |
|
Chuk | |
NM_007700 |
conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] |
KLA | 1.32 |
1.42 |
1.41 |
1.17 |
1.32 |
1.22 |
1.40 |
| ATP | 1.22 |
1.30 |
1.18 |
.97 |
1.02 |
1.00 |
1.37 |
| KLA/ATP | 1.56 |
1.61 |
1.21 |
1.09 |
.83 |
.84 |
1.17 |
|
Csnk2a1 | |
NM_007788 |
casein kinase 2, alpha 1 polypeptide (Csnk2a1), mRNA [NM_007788] |
KLA | 1.36 |
1.39 |
1.19 |
1.34 |
1.32 |
1.74 |
1.86 |
| ATP | .92 |
.88 |
1.13 |
.86 |
1.12 |
2.50 |
1.99 |
| KLA/ATP | 1.19 |
1.24 |
1.35 |
1.03 |
1.16 |
2.09 |
2.88 |
|
Csnk2a2 | |
NM_009974 |
casein kinase 2, alpha prime polypeptide (Csnk2a2), mRNA [NM_009974] |
KLA | 1.46 |
1.53 |
1.70 |
1.47 |
1.32 |
1.32 |
1.17 |
| ATP | 1.00 |
1.11 |
1.17 |
1.33 |
1.71 |
2.03 |
1.06 |
| KLA/ATP | 1.58 |
1.67 |
1.69 |
2.00 |
2.20 |
2.44 |
1.68 |
|
Csnk2b | |
NM_009975 |
casein kinase 2, beta polypeptide (Csnk2b), mRNA [NM_009975] |
KLA | 1.19 |
1.10 |
1.12 |
1.13 |
1.20 |
1.28 |
1.25 |
| ATP | 1.12 |
1.03 |
1.04 |
1.07 |
1.20 |
1.27 |
1.09 |
| KLA/ATP | 1.15 |
1.20 |
1.25 |
1.13 |
1.44 |
1.34 |
1.35 |
|
Cxcl12 | |
NM_001012477 |
chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 3, mRNA [NM_001012477] |
KLA | .91 |
.91 |
.92 |
.92 |
.91 |
1.00 |
.85 |
| ATP | 1.00 |
.99 |
1.02 |
.99 |
.91 |
.93 |
.88 |
| KLA/ATP | .89 |
.91 |
.97 |
.97 |
.94 |
.93 |
.82 |
|
Cxcl12 | |
NM_021704 |
chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 1, mRNA [NM_021704] |
KLA | 1.01 |
.96 |
1.04 |
1.04 |
.94 |
.98 |
.94 |
| ATP | 1.01 |
.92 |
.98 |
1.04 |
1.02 |
.94 |
.98 |
| KLA/ATP | 1.02 |
.98 |
1.07 |
.95 |
1.02 |
.98 |
.99 |
|
Cxcl2 | |
NM_009140 |
chemokine (C-X-C motif) ligand 2 (Cxcl2), mRNA [NM_009140] |
KLA | 20.11 |
17.63 |
13.50 |
7.78 |
9.14 |
3.98 |
10.85 |
| ATP | 10.96 |
27.84 |
145.37 |
396.18 |
303.88 |
165.35 |
21.04 |
| KLA/ATP | 33.28 |
74.00 |
189.99 |
348.56 |
93.84 |
68.75 |
64.87 |
|
Ddx58 | |
NM_172689 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (Ddx58), mRNA [NM_172689] |
KLA | 8.80 |
9.12 |
9.70 |
9.96 |
9.92 |
7.85 |
5.67 |
| ATP | 1.06 |
.89 |
.97 |
.89 |
.80 |
3.03 |
3.67 |
| KLA/ATP | 9.18 |
9.23 |
10.31 |
9.25 |
7.29 |
6.93 |
8.99 |
|
EG629860
| |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Erc1 | |
NM_053204 |
ELKS/RAB6-interacting/CAST family member 1 (Erc1), transcript variant 1, mRNA [NM_053204] |
KLA | 1.14 |
1.06 |
.94 |
.96 |
.81 |
.83 |
.81 |
| ATP | 1.06 |
1.00 |
.93 |
.81 |
.66 |
1.08 |
.99 |
| KLA/ATP | 1.02 |
1.05 |
1.04 |
.81 |
.64 |
.87 |
.85 |
|
Erc1 | |
NM_178085 |
ELKS/RAB6-interacting/CAST family member 1 (Erc1), transcript variant 2, mRNA [NM_178085] |
KLA | .97 |
.93 |
.94 |
.92 |
.91 |
.85 |
.93 |
| ATP | 1.01 |
1.01 |
.99 |
.96 |
.93 |
1.04 |
1.04 |
| KLA/ATP | .96 |
.96 |
.93 |
.93 |
.89 |
.88 |
.96 |
|
Gadd45b | |
NM_008655 |
growth arrest and DNA-damage-inducible 45 beta (Gadd45b), mRNA [NM_008655] |
KLA | 10.08 |
11.65 |
8.40 |
11.27 |
8.24 |
7.30 |
5.74 |
| ATP | 1.83 |
3.28 |
10.08 |
27.60 |
15.97 |
8.84 |
4.61 |
| KLA/ATP | 9.36 |
14.99 |
21.30 |
45.24 |
49.27 |
21.63 |
22.73 |
|
Icam1 | |
BC008626 |
intercellular adhesion molecule, mRNA (cDNA clone MGC:6195 IMAGE:3588949), complete cds [BC008626] |
KLA | 36.67 |
32.93 |
28.63 |
27.91 |
14.65 |
8.16 |
4.15 |
| ATP | .96 |
.88 |
1.50 |
3.88 |
4.98 |
3.90 |
1.01 |
| KLA/ATP | 32.58 |
31.60 |
42.74 |
32.60 |
26.00 |
13.02 |
6.01 |
|
Icam1 | |
NM_010493 |
intercellular adhesion molecule 1 (Icam1), mRNA [NM_010493] |
KLA | 15.66 |
15.20 |
12.96 |
12.31 |
9.39 |
6.17 |
3.81 |
| ATP | .96 |
1.06 |
1.21 |
4.19 |
4.33 |
3.16 |
1.06 |
| KLA/ATP | 14.31 |
15.46 |
17.84 |
17.60 |
13.77 |
8.36 |
5.42 |
|
Igh-VJ55 8 | |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 | |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 | |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 | |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 | |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Ikbkg | |
AK042138 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] |
KLA | .92 |
.87 |
.78 |
.78 |
.87 |
.88 |
.62 |
| ATP | .84 |
.71 |
.80 |
.50 |
1.15 |
2.33 |
.61 |
| KLA/ATP | .72 |
.69 |
.74 |
.48 |
1.06 |
1.97 |
.68 |
|
Ikbkg | |
NM_010547 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] |
KLA | 1.51 |
1.63 |
1.74 |
1.83 |
1.83 |
1.73 |
1.72 |
| ATP | .80 |
.79 |
.82 |
.75 |
.66 |
2.58 |
2.37 |
| KLA/ATP | 1.43 |
1.42 |
1.17 |
1.04 |
.71 |
1.54 |
3.17 |
|
Ikbkg | |
NM_178590 |
inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] |
KLA | .84 |
.93 |
.86 |
.91 |
1.03 |
.89 |
.88 |
| ATP | 1.03 |
.98 |
.68 |
.56 |
.51 |
.93 |
.68 |
| KLA/ATP | .89 |
.81 |
.55 |
.52 |
.41 |
.67 |
.65 |
|
Il1b | |
NM_008361 |
interleukin 1 beta (Il1b), mRNA [NM_008361] |
KLA | 149.78 |
133.59 |
100.91 |
116.58 |
86.48 |
89.37 |
64.72 |
| ATP | 3.49 |
13.96 |
61.44 |
70.91 |
82.12 |
162.79 |
28.18 |
| KLA/ATP | 130.32 |
139.00 |
219.12 |
148.17 |
165.44 |
172.57 |
146.98 |
|
Il1r1 | |
NM_008362 |
interleukin 1 receptor, type I (Il1r1), transcript variant 1, mRNA [NM_008362] |
KLA | 1.20 |
1.08 |
1.22 |
1.52 |
2.19 |
2.32 |
1.61 |
| ATP | 1.10 |
.96 |
1.18 |
1.56 |
8.14 |
9.56 |
7.54 |
| KLA/ATP | 1.22 |
1.13 |
1.37 |
1.85 |
4.54 |
6.85 |
8.96 |
|
Irak1 | |
NM_008363 |
interleukin-1 receptor-associated kinase 1 (Irak1), mRNA [NM_008363] |
KLA | .67 |
.67 |
.64 |
.56 |
.58 |
.58 |
.84 |
| ATP | 1.02 |
1.10 |
.94 |
1.14 |
.81 |
.54 |
.87 |
| KLA/ATP | .72 |
.72 |
.57 |
.67 |
.51 |
.43 |
.62 |
|
Irak4 | |
NM_029926 |
interleukin-1 receptor-associated kinase 4 (Irak4), mRNA [NM_029926] |
KLA | .82 |
.86 |
.78 |
.82 |
.95 |
1.21 |
1.22 |
| ATP | 1.02 |
1.18 |
.95 |
1.10 |
.79 |
.85 |
.82 |
| KLA/ATP | .86 |
.89 |
.77 |
.90 |
.78 |
.96 |
.88 |
|
LOC10004 6483 | |
XM_001476285 |
ref|PREDICTED: Mus musculus similar to casein kinase II, alpha prime subunit (LOC100046483), mRNA [XM_001476285] |
KLA | .97 |
.94 |
.94 |
.88 |
.84 |
.76 |
.88 |
| ATP | 1.06 |
1.04 |
.89 |
.82 |
.87 |
.70 |
.56 |
| KLA/ATP | 1.03 |
1.00 |
.88 |
.75 |
.73 |
.66 |
.43 |
|
Lat | |
NM_010689 |
linker for activation of T cells (Lat), mRNA [NM_010689] |
KLA | .91 |
.95 |
.94 |
.87 |
.76 |
.63 |
.48 |
| ATP | .97 |
.99 |
1.01 |
1.50 |
1.59 |
1.49 |
1.00 |
| KLA/ATP | .91 |
1.04 |
.93 |
1.15 |
1.11 |
.96 |
.65 |
|
Lbp | |
NM_008489 |
lipopolysaccharide binding protein (Lbp), mRNA [NM_008489] |
KLA | 1.01 |
1.01 |
.94 |
1.02 |
1.03 |
1.06 |
1.00 |
| ATP | 1.00 |
.99 |
.96 |
1.03 |
.91 |
.89 |
.84 |
| KLA/ATP | .98 |
.96 |
1.01 |
.93 |
1.00 |
.95 |
.83 |
|
Lck | |
NM_010693 |
lymphocyte protein tyrosine kinase (Lck), mRNA [NM_010693] |
KLA | 18.74 |
17.97 |
23.64 |
20.20 |
17.34 |
8.29 |
1.29 |
| ATP | 1.00 |
1.04 |
1.28 |
1.30 |
1.48 |
2.55 |
1.44 |
| KLA/ATP | 21.76 |
24.22 |
23.73 |
23.04 |
22.66 |
12.06 |
2.90 |
|
Lrdd | |
NM_022654 |
leucine-rich and death domain containing (Lrdd), mRNA [NM_022654] |
KLA | .93 |
.97 |
1.01 |
.99 |
.96 |
1.02 |
.78 |
| ATP | 1.03 |
1.01 |
.91 |
.91 |
.75 |
.82 |
.73 |
| KLA/ATP | 1.02 |
1.03 |
1.06 |
1.27 |
1.01 |
1.03 |
.95 |
|
Lta | |
NM_010735 |
lymphotoxin A (Lta), mRNA [NM_010735] |
KLA | 1.95 |
2.18 |
2.41 |
2.18 |
2.50 |
2.26 |
1.79 |
| ATP | 1.01 |
1.00 |
1.10 |
1.55 |
1.24 |
1.09 |
1.07 |
| KLA/ATP | 2.16 |
2.23 |
1.85 |
2.11 |
1.60 |
1.31 |
1.33 |
|
Ltb | |
NM_008518 |
lymphotoxin B (Ltb), mRNA [NM_008518] |
KLA | 2.41 |
2.52 |
2.49 |
3.05 |
3.54 |
4.63 |
1.94 |
| ATP | 1.00 |
.92 |
1.28 |
1.57 |
1.77 |
1.64 |
.98 |
| KLA/ATP | 2.22 |
2.68 |
2.81 |
3.15 |
4.88 |
4.53 |
2.01 |
|
Ltbr | |
NM_010736 |
lymphotoxin B receptor (Ltbr), mRNA [NM_010736] |
KLA | .78 |
.77 |
.80 |
.95 |
1.08 |
1.39 |
1.36 |
| ATP | .94 |
.86 |
1.00 |
.83 |
.74 |
1.18 |
1.37 |
| KLA/ATP | .69 |
.71 |
.74 |
.68 |
.85 |
1.04 |
1.69 |
|
Ly96 | |
NM_016923 |
lymphocyte antigen 96 (Ly96), mRNA [NM_016923] |
KLA | 2.25 |
2.07 |
2.39 |
2.38 |
2.38 |
2.30 |
2.14 |
| ATP | 1.19 |
1.02 |
1.35 |
1.20 |
1.69 |
2.83 |
1.93 |
| KLA/ATP | 2.36 |
2.28 |
3.07 |
2.62 |
2.68 |
2.34 |
3.13 |
|
Lyn | |
NM_010747 |
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] |
KLA | 2.48 |
2.80 |
3.76 |
3.81 |
5.30 |
4.57 |
2.46 |
| ATP | 1.06 |
1.18 |
.82 |
.97 |
.74 |
1.45 |
1.21 |
| KLA/ATP | 2.82 |
3.16 |
2.24 |
2.87 |
1.73 |
1.80 |
2.63 |
|
Malt1 | |
AK172081 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830035G05 product:unclassifiable, full insert sequence [AK172081] |
KLA | 8.85 |
8.52 |
6.90 |
6.44 |
8.01 |
3.16 |
3.02 |
| ATP | 1.37 |
1.55 |
2.57 |
6.23 |
6.73 |
5.82 |
1.27 |
| KLA/ATP | 9.01 |
10.69 |
14.85 |
12.51 |
4.33 |
4.50 |
6.89 |
|
Malt1 | |
NM_172833 |
mucosa associated lymphoid tissue lymphoma translocation gene 1 (Malt1), mRNA [NM_172833] |
KLA | 17.74 |
16.14 |
15.00 |
9.66 |
9.87 |
4.22 |
3.54 |
| ATP | 1.20 |
1.19 |
2.20 |
5.12 |
10.20 |
8.16 |
1.25 |
| KLA/ATP | 19.07 |
18.41 |
21.75 |
20.07 |
13.32 |
7.72 |
8.40 |
|
Map3k14 | |
NM_016896 |
mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] |
KLA | .32 |
.30 |
.40 |
.52 |
1.08 |
1.14 |
.94 |
| ATP | 1.18 |
1.24 |
1.13 |
.85 |
.82 |
.84 |
.99 |
| KLA/ATP | .33 |
.30 |
.34 |
.50 |
1.02 |
.84 |
1.43 |
|
Map3k7 | |
NM_172688 |
mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] |
KLA | 1.48 |
1.49 |
1.51 |
1.24 |
1.21 |
1.19 |
1.61 |
| ATP | 1.10 |
1.16 |
1.03 |
1.03 |
1.12 |
1.61 |
1.61 |
| KLA/ATP | 1.43 |
1.56 |
1.05 |
1.15 |
.85 |
1.48 |
1.76 |
|
Map3k7ip 1 | |
NM_025609 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 1 (Map3k7ip1), mRNA [NM_025609] |
KLA | .32 |
.30 |
.35 |
.56 |
.67 |
.82 |
.76 |
| ATP | .95 |
.81 |
.80 |
.42 |
.35 |
.40 |
.80 |
| KLA/ATP | .33 |
.30 |
.37 |
.20 |
.45 |
.62 |
.65 |
|
Map3k7ip 2 | |
AK086230 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930015C19 product:inferred: Mus musculus, Similar to TAK1-binding protein 2; KIAA0733 protein, clone MGC:8010 IMAGE:3586132, mRNA, complete cds, full insert sequence. [A |
KLA | 1.14 |
1.02 |
1.07 |
1.03 |
1.13 |
1.02 |
.96 |
| ATP | 1.00 |
.88 |
.92 |
.90 |
1.06 |
.96 |
.94 |
| KLA/ATP | 1.05 |
1.00 |
.90 |
.98 |
1.02 |
.97 |
.97 |
|
Map3k7ip 2 | |
NM_138667 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 2 (Map3k7ip2), mRNA [NM_138667] |
KLA | 3.43 |
3.22 |
3.19 |
2.41 |
2.13 |
1.51 |
1.10 |
| ATP | 1.08 |
1.08 |
.86 |
.81 |
1.30 |
1.32 |
1.02 |
| KLA/ATP | 3.34 |
3.66 |
3.00 |
2.58 |
1.80 |
1.52 |
1.61 |
|
Map3k7ip 3 | |
NM_025729 |
mitogen-activated protein kinase kinase kinase 7 interacting protein 3 (Map3k7ip3), mRNA [NM_025729] |
KLA | 1.21 |
1.05 |
1.20 |
1.24 |
1.12 |
1.26 |
1.18 |
| ATP | 1.02 |
.88 |
1.07 |
.64 |
1.38 |
1.88 |
.95 |
| KLA/ATP | 1.13 |
1.11 |
1.21 |
.75 |
1.58 |
1.74 |
1.38 |
|
Mm.14928 0 | |
34328395 |
Unknown |
KLA | 1.35 |
1.44 |
1.59 |
1.51 |
1.51 |
1.28 |
1.54 |
| ATP | .98 |
.97 |
1.05 |
1.08 |
1.19 |
.75 |
.71 |
| KLA/ATP | 1.31 |
1.34 |
1.22 |
1.42 |
1.28 |
.89 |
.95 |
|
Mm.15898 1 | |
142388182 |
Unknown |
KLA | .25 |
.22 |
.31 |
.50 |
.85 |
1.11 |
.83 |
| ATP | 1.02 |
.94 |
1.31 |
.76 |
.73 |
.96 |
.92 |
| KLA/ATP | .24 |
.22 |
.34 |
.38 |
1.16 |
.96 |
1.23 |
|
Mm.1741 | |
31982052 |
Unknown |
KLA | 4.05 |
3.90 |
3.12 |
3.55 |
4.00 |
3.37 |
2.25 |
| ATP | 1.01 |
1.01 |
1.44 |
2.36 |
3.07 |
3.54 |
1.27 |
| KLA/ATP | 4.19 |
3.74 |
4.02 |
4.02 |
3.13 |
2.82 |
3.33 |
|
Mm.23692
| |
164565453 |
Unknown |
KLA | .83 |
.77 |
.72 |
.65 |
.61 |
.75 |
.80 |
| ATP | .77 |
.94 |
1.03 |
.63 |
.61 |
.74 |
.59 |
| KLA/ATP | .58 |
.78 |
.77 |
.52 |
.51 |
.56 |
.30 |
|
Mm.24004 7 | |
118130430 |
Unknown |
KLA | 1.09 |
1.07 |
1.01 |
1.00 |
1.04 |
1.05 |
.97 |
| ATP | .98 |
1.00 |
1.05 |
.97 |
1.05 |
1.02 |
1.05 |
| KLA/ATP | .98 |
1.04 |
1.16 |
1.06 |
1.06 |
.96 |
1.02 |
|
Mm.33565 9 | |
160333365 |
Unknown |
KLA | 5.54 |
4.69 |
3.93 |
3.03 |
2.00 |
1.91 |
1.69 |
| ATP | .98 |
.81 |
1.01 |
.78 |
.68 |
1.71 |
1.10 |
| KLA/ATP | 5.05 |
4.44 |
5.07 |
2.38 |
1.34 |
1.88 |
2.00 |
|
Mm.38049
| |
118130391 |
Unknown |
KLA | .67 |
.65 |
.73 |
.92 |
.63 |
.81 |
.76 |
| ATP | .93 |
.92 |
1.08 |
.54 |
.45 |
1.48 |
1.56 |
| KLA/ATP | .57 |
.65 |
.98 |
.67 |
.44 |
.78 |
1.16 |
|
Mm.44463
| |
118129851 |
Unknown |
KLA | 1.01 |
.98 |
.97 |
1.02 |
.93 |
1.06 |
1.05 |
| ATP | .97 |
1.01 |
1.04 |
1.06 |
1.02 |
1.08 |
.97 |
| KLA/ATP | 1.02 |
1.06 |
.95 |
1.04 |
1.09 |
1.14 |
1.03 |
|
Mm.46002 4 | |
38348245 |
Unknown |
KLA | 1.22 |
1.25 |
1.25 |
1.19 |
1.22 |
1.47 |
1.14 |
| ATP | 1.03 |
.94 |
1.01 |
1.01 |
2.67 |
2.31 |
1.37 |
| KLA/ATP | 1.35 |
1.19 |
1.27 |
1.22 |
1.99 |
1.83 |
1.45 |
|
Myd88 | |
NM_010851 |
myeloid differentiation primary response gene 88 (Myd88), mRNA [NM_010851] |
KLA | 3.35 |
3.51 |
3.91 |
4.13 |
4.13 |
3.62 |
2.53 |
| ATP | .99 |
.96 |
.79 |
.75 |
.93 |
2.15 |
1.60 |
| KLA/ATP | 3.37 |
3.52 |
3.52 |
3.48 |
2.81 |
3.03 |
3.33 |
|
Nfkb1 | |
BC050841 |
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] |
KLA | 5.81 |
4.96 |
4.77 |
3.21 |
3.37 |
2.00 |
1.71 |
| ATP | 1.39 |
1.52 |
3.25 |
12.63 |
13.64 |
4.80 |
1.08 |
| KLA/ATP | 7.21 |
8.69 |
19.53 |
23.93 |
11.70 |
2.85 |
2.01 |
|
Nfkb1 | |
M57999 |
gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] |
KLA | 8.55 |
7.87 |
7.35 |
6.13 |
3.51 |
1.85 |
1.38 |
| ATP | .98 |
.96 |
1.21 |
3.06 |
5.29 |
4.67 |
.69 |
| KLA/ATP | 7.32 |
7.20 |
8.71 |
10.82 |
5.55 |
2.77 |
1.54 |
|
Nfkb2 | |
NM_019408 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2), mRNA [NM_019408] |
KLA | 7.31 |
7.92 |
7.95 |
6.42 |
6.41 |
4.42 |
2.81 |
| ATP | .99 |
.98 |
.72 |
1.48 |
2.80 |
5.31 |
1.44 |
| KLA/ATP | 8.25 |
7.93 |
6.51 |
7.68 |
5.08 |
4.38 |
4.86 |
|
Nfkbia | |
NM_010907 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] |
KLA | 18.65 |
18.46 |
13.63 |
17.88 |
14.25 |
9.17 |
7.92 |
| ATP | .91 |
1.09 |
7.11 |
32.39 |
17.44 |
10.49 |
1.72 |
| KLA/ATP | 15.57 |
17.66 |
15.73 |
23.91 |
13.83 |
10.73 |
9.48 |
|
Parp1 | |
NM_007415 |
poly (ADP-ribose) polymerase family, member 1 (Parp1), mRNA [NM_007415] |
KLA | .56 |
.58 |
.56 |
.44 |
.45 |
.46 |
.49 |
| ATP | 1.03 |
1.11 |
.93 |
.92 |
.66 |
.20 |
.46 |
| KLA/ATP | .65 |
.55 |
.46 |
.54 |
.33 |
.24 |
.22 |
|
Parp1 | |
X14206 |
gb|Mouse mRNA for poly (ADP-ribose) polymerase (EC 2.4.2.30). [X14206] |
KLA | .57 |
.56 |
.54 |
.43 |
.40 |
.42 |
.47 |
| ATP | 1.01 |
1.09 |
.95 |
.95 |
.59 |
.19 |
.43 |
| KLA/ATP | .59 |
.55 |
.46 |
.49 |
.32 |
.20 |
.20 |
|
Pias4 | |
NM_021501 |
protein inhibitor of activated STAT 4 (Pias4), mRNA [NM_021501] |
KLA | .97 |
1.13 |
1.26 |
1.38 |
1.87 |
1.63 |
1.62 |
| ATP | 1.12 |
1.30 |
.89 |
1.24 |
1.93 |
1.64 |
1.92 |
| KLA/ATP | 1.33 |
1.11 |
.74 |
1.30 |
1.61 |
2.07 |
2.69 |
|
Plau | |
NM_008873 |
plasminogen activator, urokinase (Plau), mRNA [NM_008873] |
KLA | .28 |
.27 |
.22 |
.23 |
.19 |
.25 |
.27 |
| ATP | .99 |
1.19 |
1.63 |
2.44 |
1.52 |
.49 |
1.12 |
| KLA/ATP | .26 |
.29 |
.32 |
.40 |
.35 |
.32 |
.48 |
|
Plcg2 | |
NM_172285 |
phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] |
KLA | .76 |
.74 |
.68 |
.66 |
.71 |
.92 |
.95 |
| ATP | .96 |
.90 |
.95 |
.87 |
.81 |
.79 |
.91 |
| KLA/ATP | .76 |
.71 |
.69 |
.62 |
.72 |
.78 |
.68 |
|
Prkcb1 | |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
Prkcq | |
AK085546 |
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630039J01 product:protein kinase C, theta, full insert sequence [AK085546] |
KLA | .98 |
.99 |
1.01 |
1.00 |
.95 |
.98 |
.97 |
| ATP | 1.06 |
.98 |
1.02 |
1.00 |
.99 |
.99 |
1.04 |
| KLA/ATP | .91 |
1.01 |
.84 |
1.02 |
1.03 |
1.00 |
1.03 |
|
Prkcq | |
NM_008859 |
protein kinase C, theta (Prkcq), mRNA [NM_008859] |
KLA | 1.04 |
1.07 |
1.00 |
1.06 |
1.02 |
.91 |
.87 |
| ATP | 1.06 |
.97 |
.97 |
.99 |
.94 |
1.00 |
.89 |
| KLA/ATP | 1.09 |
1.00 |
1.15 |
1.14 |
.98 |
1.07 |
.96 |
|
Ptgs2 | |
NM_011198 |
prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA [NM_011198] |
KLA | 181.04 |
220.88 |
218.58 |
132.79 |
103.05 |
22.69 |
18.02 |
| ATP | 2.47 |
9.45 |
52.13 |
208.62 |
271.22 |
306.11 |
6.86 |
| KLA/ATP | 233.39 |
387.29 |
617.86 |
###.## |
608.44 |
290.80 |
112.22 |
|
Rela | |
NM_009045 |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] |
KLA | 2.05 |
2.05 |
2.07 |
1.75 |
1.83 |
1.58 |
1.33 |
| ATP | 1.03 |
1.08 |
1.10 |
1.44 |
1.61 |
2.48 |
1.05 |
| KLA/ATP | 2.17 |
2.27 |
2.05 |
2.47 |
1.93 |
2.35 |
2.02 |
|
Relb | |
NM_009046 |
avian reticuloendotheliosis viral (v-rel) oncogene related B (Relb), mRNA [NM_009046] |
KLA | 4.39 |
4.46 |
3.54 |
3.47 |
4.36 |
3.18 |
2.72 |
| ATP | 1.01 |
1.07 |
1.23 |
2.66 |
3.23 |
3.50 |
1.24 |
| KLA/ATP | 4.43 |
4.52 |
3.56 |
4.10 |
2.85 |
2.92 |
3.30 |
|
Ripk1 | |
NM_009068 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (Ripk1), mRNA [NM_009068] |
KLA | 1.32 |
1.33 |
1.50 |
1.09 |
1.00 |
1.11 |
1.13 |
| ATP | .98 |
.94 |
.60 |
.59 |
1.35 |
1.56 |
1.45 |
| KLA/ATP | 1.48 |
1.30 |
1.01 |
1.05 |
1.36 |
1.53 |
1.37 |
|
Syk | |
NM_011518 |
spleen tyrosine kinase (Syk), mRNA [NM_011518] |
KLA | 2.48 |
2.59 |
2.57 |
2.26 |
3.29 |
3.75 |
3.19 |
| ATP | .96 |
.85 |
.59 |
1.01 |
2.80 |
3.77 |
2.11 |
| KLA/ATP | 2.56 |
2.09 |
1.16 |
1.35 |
2.50 |
4.33 |
5.10 |
|
Ticam1 | |
NM_174989 |
toll-like receptor adaptor molecule 1 (Ticam1), mRNA [NM_174989] |
KLA | 1.45 |
1.63 |
2.02 |
2.36 |
3.12 |
2.34 |
2.21 |
| ATP | 1.16 |
1.19 |
.90 |
2.58 |
4.78 |
2.04 |
1.80 |
| KLA/ATP | 1.79 |
1.71 |
1.07 |
2.89 |
5.60 |
3.26 |
3.50 |
|
Ticam2 | |
NM_173394 |
toll-like receptor adaptor molecule 2 (Ticam2), mRNA [NM_173394] |
KLA | 1.28 |
1.35 |
1.64 |
1.79 |
1.80 |
1.34 |
2.01 |
| ATP | 1.02 |
1.02 |
1.00 |
1.14 |
1.16 |
.70 |
.88 |
| KLA/ATP | 1.49 |
1.50 |
1.14 |
1.41 |
1.13 |
.89 |
1.40 |
|
Tirap | |
AK081514 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130027E04 product:toll-interleukin 1 receptor (TIR) domain-containing adaptor protein, full insert sequence [AK081514] |
KLA | 1.36 |
1.33 |
1.35 |
1.41 |
1.36 |
1.45 |
1.22 |
| ATP | .93 |
.87 |
.82 |
.45 |
.78 |
1.93 |
1.32 |
| KLA/ATP | 1.35 |
1.37 |
1.30 |
.83 |
1.17 |
1.75 |
2.10 |
|
Tirap | |
NM_054096 |
toll-interleukin 1 receptor (TIR) domain-containing adaptor protein (Tirap), mRNA [NM_054096] |
KLA | 1.88 |
1.70 |
1.69 |
1.74 |
1.82 |
1.69 |
1.31 |
| ATP | 1.12 |
1.10 |
.75 |
.56 |
1.03 |
2.52 |
1.67 |
| KLA/ATP | 1.60 |
1.75 |
1.69 |
1.25 |
1.41 |
2.27 |
3.21 |
|
Tlr4 | |
NM_021297 |
toll-like receptor 4 (Tlr4), mRNA [NM_021297] |
KLA | .69 |
.61 |
.75 |
.94 |
.64 |
.81 |
.73 |
| ATP | .95 |
.90 |
1.12 |
.56 |
.47 |
1.51 |
1.53 |
| KLA/ATP | .57 |
.62 |
1.01 |
.64 |
.39 |
.73 |
1.13 |
|
Tnf | |
NM_013693 |
tumor necrosis factor (Tnf), mRNA [NM_013693] |
KLA | 13.35 |
12.76 |
10.71 |
9.03 |
10.64 |
7.39 |
8.32 |
| ATP | 2.01 |
2.48 |
8.27 |
19.20 |
9.72 |
4.09 |
1.49 |
| KLA/ATP | 12.72 |
15.76 |
12.73 |
17.34 |
5.10 |
3.61 |
6.07 |
|
Tnfaip3 | |
NM_009397 |
tumor necrosis factor, alpha-induced protein 3 (Tnfaip3), mRNA [NM_009397] |
KLA | 29.69 |
27.73 |
21.42 |
18.86 |
14.42 |
8.13 |
7.48 |
| ATP | 1.73 |
4.86 |
21.57 |
43.06 |
30.03 |
18.86 |
8.31 |
| KLA/ATP | 29.39 |
35.88 |
40.64 |
52.71 |
33.19 |
25.38 |
17.75 |
|
Tnfrsf11 a | |
NM_009399 |
tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a), mRNA [NM_009399] |
KLA | 1.43 |
1.33 |
1.36 |
1.58 |
1.87 |
1.83 |
1.47 |
| ATP | 1.07 |
1.17 |
1.02 |
1.19 |
.95 |
.82 |
1.13 |
| KLA/ATP | 1.55 |
1.46 |
1.16 |
1.46 |
.79 |
.95 |
1.92 |
|
Tnfrsf13 c | |
NM_028075 |
tumor necrosis factor receptor superfamily, member 13c (Tnfrsf13c), mRNA [NM_028075] |
KLA | 1.05 |
1.04 |
1.05 |
1.01 |
1.05 |
1.00 |
.92 |
| ATP | 1.03 |
1.01 |
1.01 |
.99 |
1.04 |
1.03 |
1.04 |
| KLA/ATP | 1.05 |
1.07 |
1.10 |
1.04 |
1.02 |
.94 |
1.00 |
|
Tnfrsf1a
| |
NM_011609 |
tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] |
KLA | 1.74 |
1.71 |
1.90 |
2.16 |
1.95 |
1.74 |
1.16 |
| ATP | .95 |
.83 |
.55 |
.41 |
.41 |
1.55 |
1.32 |
| KLA/ATP | 1.58 |
1.49 |
1.19 |
1.03 |
.98 |
2.02 |
2.10 |
|
Tnfsf11 | |
NM_011613 |
tumor necrosis factor (ligand) superfamily, member 11 (Tnfsf11), mRNA [NM_011613] |
KLA | 1.00 |
1.00 |
1.08 |
.96 |
.97 |
1.01 |
.96 |
| ATP | 1.01 |
1.05 |
.97 |
.86 |
1.05 |
1.03 |
1.01 |
| KLA/ATP | 1.04 |
1.05 |
.99 |
1.04 |
1.01 |
1.02 |
.99 |
|
Tnfsf13b
| |
ENSMUST00000033892 |
ens|Tumor necrosis factor ligand superfamily member 13B (B cell-activating factor) (BAFF) (CD257 antigen) [Contains: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form]. [ |
KLA | .95 |
.99 |
.93 |
.92 |
.94 |
.94 |
.92 |
| ATP | .90 |
.92 |
1.01 |
.91 |
.93 |
.95 |
.92 |
| KLA/ATP | .94 |
.89 |
1.17 |
1.03 |
.98 |
.93 |
.90 |
|
Tnfsf13b
| |
NM_033622 |
tumor necrosis factor (ligand) superfamily, member 13b (Tnfsf13b), mRNA [NM_033622] |
KLA | .87 |
.87 |
.92 |
.79 |
.74 |
.80 |
1.17 |
| ATP | .97 |
.87 |
.83 |
.81 |
.79 |
.57 |
.38 |
| KLA/ATP | .91 |
.86 |
.87 |
.88 |
1.02 |
.89 |
.49 |
|
Tnfsf14 | |
NM_019418 |
tumor necrosis factor (ligand) superfamily, member 14 (Tnfsf14), mRNA [NM_019418] |
KLA | .57 |
.66 |
.55 |
.82 |
.48 |
.29 |
.22 |
| ATP | 1.16 |
1.25 |
1.61 |
8.55 |
24.98 |
15.54 |
3.28 |
| KLA/ATP | .88 |
.70 |
.86 |
3.41 |
17.39 |
10.12 |
1.56 |
|
Tradd | |
NM_001033161 |
TNFRSF1A-associated via death domain (Tradd), mRNA [NM_001033161] |
KLA | .77 |
.71 |
.82 |
.89 |
.89 |
1.11 |
1.06 |
| ATP | 1.00 |
.90 |
1.01 |
.73 |
.59 |
1.34 |
1.50 |
| KLA/ATP | .79 |
.73 |
.83 |
.63 |
.72 |
1.11 |
1.73 |
|
Traf1 | |
NM_009421 |
Tnf receptor-associated factor 1 (Traf1), mRNA [NM_009421] |
KLA | 44.86 |
39.03 |
38.11 |
34.21 |
36.49 |
19.69 |
14.75 |
| ATP | 1.14 |
1.04 |
1.98 |
8.16 |
16.79 |
30.81 |
6.36 |
| KLA/ATP | 46.20 |
45.67 |
45.63 |
38.00 |
27.26 |
31.47 |
63.83 |
|
Traf2 | |
NM_009422 |
Tnf receptor-associated factor 2 (Traf2), mRNA [NM_009422] |
KLA | 3.38 |
3.62 |
3.49 |
3.36 |
3.49 |
3.39 |
2.68 |
| ATP | .97 |
1.04 |
1.00 |
1.10 |
1.54 |
2.40 |
1.55 |
| KLA/ATP | 3.38 |
3.16 |
2.93 |
2.74 |
2.67 |
3.11 |
4.70 |
|
Traf3 | |
NM_011632 |
Tnf receptor-associated factor 3 (Traf3), transcript variant 1, mRNA [NM_011632] |
KLA | .52 |
.49 |
.51 |
.49 |
.80 |
.98 |
1.22 |
| ATP | .93 |
.92 |
.95 |
1.13 |
2.70 |
1.80 |
1.42 |
| KLA/ATP | .56 |
.50 |
.49 |
1.07 |
2.94 |
1.92 |
1.65 |
|
Traf5 | |
NM_011633 |
Tnf receptor-associated factor 5 (Traf5), mRNA [NM_011633] |
KLA | 1.82 |
1.92 |
1.93 |
2.10 |
2.75 |
2.08 |
1.00 |
| ATP | 1.02 |
1.04 |
1.10 |
.78 |
3.79 |
2.22 |
1.42 |
| KLA/ATP | 1.70 |
1.89 |
1.85 |
1.64 |
5.40 |
2.10 |
1.83 |
|
Traf6 | |
NM_009424 |
Tnf receptor-associated factor 6 (Traf6), mRNA [NM_009424] |
KLA | 1.19 |
1.28 |
1.34 |
1.20 |
1.23 |
1.23 |
1.28 |
| ATP | 1.06 |
1.12 |
.92 |
1.15 |
2.46 |
1.84 |
1.40 |
| KLA/ATP | 1.32 |
1.37 |
.89 |
1.16 |
1.45 |
1.49 |
1.46 |
|
Trim25 | |
NM_009546 |
tripartite motif-containing 25 (Trim25), mRNA [NM_009546] |
KLA | 3.93 |
4.08 |
4.13 |
3.67 |
3.19 |
3.12 |
3.13 |
| ATP | 1.02 |
1.00 |
.92 |
1.22 |
2.80 |
3.73 |
3.72 |
| KLA/ATP | 4.17 |
4.41 |
4.23 |
4.23 |
5.38 |
5.22 |
7.68 |
|
Ube2i | |
BC037635 |
ubiquitin-conjugating enzyme E2I, mRNA (cDNA clone MGC:46871 IMAGE:4951933), complete cds. [BC037635] |
KLA | .79 |
.80 |
.78 |
.82 |
.95 |
.90 |
.98 |
| ATP | .96 |
1.00 |
.77 |
.96 |
1.41 |
1.01 |
1.00 |
| KLA/ATP | .80 |
.83 |
.68 |
.89 |
1.03 |
.93 |
.79 |
|
Ube2i | |
NM_011665 |
ubiquitin-conjugating enzyme E2I (Ube2i), mRNA [NM_011665] |
KLA | .75 |
.76 |
.74 |
.71 |
.70 |
.63 |
.78 |
| ATP | 1.03 |
1.02 |
.95 |
1.02 |
.93 |
.66 |
.75 |
| KLA/ATP | .81 |
.80 |
.71 |
.80 |
.75 |
.60 |
.61 |
|
Vcam1 | |
NM_011693 |
vascular cell adhesion molecule 1 (Vcam1), mRNA [NM_011693] |
KLA | 18.71 |
22.30 |
20.87 |
18.09 |
13.61 |
6.09 |
2.09 |
| ATP | 1.08 |
1.00 |
1.56 |
4.23 |
5.09 |
5.04 |
1.50 |
| KLA/ATP | 19.09 |
25.02 |
26.43 |
25.42 |
20.08 |
11.45 |
6.67 |
|
Xiap | |
NM_009688 |
X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] |
KLA | 1.61 |
1.63 |
1.62 |
1.52 |
1.34 |
1.27 |
1.11 |
| ATP | 1.03 |
1.01 |
.99 |
.96 |
.88 |
1.19 |
1.25 |
| KLA/ATP | 1.64 |
1.63 |
1.54 |
1.33 |
1.08 |
1.19 |
1.72 |
|
Zap70 | |
NM_009539 |
zeta-chain (TCR) associated protein kinase (Zap70), mRNA [NM_009539] |
KLA | .94 |
.88 |
.84 |
.86 |
1.01 |
.92 |
.94 |
| ATP | 1.02 |
.99 |
.87 |
.87 |
1.58 |
.98 |
.96 |
| KLA/ATP | .94 |
.82 |
.83 |
.77 |
1.09 |
.93 |
1.02 |
|